Welcome to our dedicated page for AC Immune SA news (Ticker: $ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune SA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AC Immune SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AC Immune SA's position in the market.
The clinical-stage biopharmaceutical company AC Immune (NASDAQ: ACIU) announced its participation in the Jefferies 2024 Global Healthcare Conference in New York, scheduled for June 5-6, 2024.
Company management will engage in a fireside chat on June 5 at 3:30 PM (ET), which can be accessed via webcast. Additionally, AC Immune will hold one-on-one meetings with investors. This involvement aims to highlight their precision medicine advancements for neurodegenerative diseases.
The webcast and an archived replay will be available on AC Immune’s website.
AC Immune reported its first quarter 2024 financial results and corporate update, highlighting a landmark deal with Takeda for ACI-24.060 with $100 million upfront and potential payments of up to $2.1 billion. The ACI-24.060 ABATE Phase 2 trial is on track to report results in Q2 2024, and the ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease is progressing. The company has a three-year cash runway with CHF 104.8 million. Financially, the company had a cash balance of CHF 104.8 million, R&D expenses of CHF 15.2 million, and reported a net loss of CHF 17.9 million for the quarter.
AC Immune and Takeda have signed an exclusive option and license agreement for ACI-24.060, an active immunotherapy targeting Amyloid Beta for Alzheimer's disease. Takeda will pay AC Immune $100 million upfront, with additional potential milestones totaling around $2.1 billion. AC Immune will host a conference call and webcast to discuss the agreement.